Literature DB >> 14598247

Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis.

Thomas Ullman1, Victoria Croog, Noam Harpaz, David Sachar, Steven Itzkowitz.   

Abstract

BACKGROUND & AIMS: Long-standing ulcerative colitis has long been recognized as a risk factor for colorectal cancer, but there is still no universal consensus on the optimal management of ulcerative colitis patients with low-grade dysplasia in flat mucosa. Some authorities favor prompt colectomy, whereas others recommend continued surveillance. The purpose of our study was to determine the frequency with which flat low-grade dysplasia in ulcerative colitis progresses to advanced neoplasia (high-grade dysplasia or colorectal cancer) and whether specific variables could predict such progression.
METHODS: We reviewed the medical histories, colonoscopic findings, and surgical and pathology reports of 46 patients with ulcerative colitis diagnosed with flat low-grade dysplasia on a surveillance colonoscopy. The rates of neoplastic progression, as well as the frequency of advanced neoplasia, were tabulated. We correlated progression with several clinical and colonoscopic variables: the number of biopsy samples positive for flat low-grade dysplasia, the duration and anatomic extent of disease, patient age, and medication use.
RESULTS: Among these 46 patients, there were 7 cases of colorectal cancer, 5 of which were stage II or higher. Unexpected advanced neoplasia occurred in 4 of 17 (23.5%) patients who underwent colectomy for flat low-grade dysplasia. On an actuarial basis, the rate of neoplastic progression was 53% at 5 years. No clinical features predicted progression to advanced neoplasia. Cancers, including 2 at advanced stages, developed despite frequent follow-up surveillance examinations.
CONCLUSIONS: A finding of flat low-grade dysplasia during ulcerative colitis surveillance is a strong predictor of progression to advanced neoplasia. Early colectomy should be recommended for such patients.

Entities:  

Mesh:

Year:  2003        PMID: 14598247     DOI: 10.1016/j.gastro.2003.08.023

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  77 in total

1.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Random versus targeted biopsies for colorectal cancer surveillance in inflammatory bowel disease.

Authors:  Tasneem Ahmed; Jennifer Monti; Bret Lashner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

3.  Epidermal growth factor receptor inhibits colitis-associated cancer in mice.

Authors:  Philip E Dubé; Fang Yan; Shivesh Punit; Nandini Girish; Steven J McElroy; M Kay Washington; D Brent Polk
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

4.  Surveillance of dysplasia in inflammatory bowel disease: The gastroenterologist-pathologist partnership.

Authors:  David T Rubin; Jerrold R Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11       Impact factor: 11.382

Review 5.  The approach to dysplasia surveillance in inflammatory bowel disease.

Authors:  Remo Panaccione
Journal:  Can J Gastroenterol       Date:  2006-04       Impact factor: 3.522

6.  The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice.

Authors:  Gerold Bongers; David Maussang; Luciana R Muniz; Vanessa M Noriega; Alberto Fraile-Ramos; Nick Barker; Federica Marchesi; Nanthakumar Thirunarayanan; Henry F Vischer; Lihui Qin; Lloyd Mayer; Noam Harpaz; Rob Leurs; Glaucia C Furtado; Hans Clevers; Domenico Tortorella; Martine J Smit; Sergio A Lira
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

Review 7.  Inflammatory bowel disease: the problems of dysplasia and surveillance.

Authors:  P J Mitchell; E Salmo; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-11-30       Impact factor: 3.781

8.  Development of fatal colitis in FVB mice infected with Citrobacter rodentium.

Authors:  Diana Borenshtein; Prashant R Nambiar; Elizabeth B Groff; James G Fox; David B Schauer
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

Review 9.  Endoscopic and pathological aspects of colitis-associated dysplasia.

Authors:  Fiona D M van Schaik; G Johan A Offerhaus; Marguerite E I Schipper; Peter D Siersema; Frank P Vleggaar; Bas Oldenburg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-22       Impact factor: 46.802

Review 10.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.